Abstracts
Vol. 2 No. 13 (2006)
https://doi.org/10.4081/hmr.v2i13.493

Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 10 June 2009
212
Views
488
Downloads

Authors

U Wollina
support@pagepress.org
Liposomes are lamellar structures composed of a lipid bilayer. They are used as carriers for different drugs. The present paper reviews the use of intravenous liposomal anticancer drugs in dermato-oncology. The broadest application is found today for liposomal anthracyclines, i.e. doxorubicin and daunorubicin. There is clear evidence for liposomal drug efficacy and safety cutaneous T-cell lymphoma (CTCL) with response rates about 80-90%. Randomized, double-blinded prospective controlled trials are on the way.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects. (2009). Hematology Meeting Reports, 2(13). https://doi.org/10.4081/hmr.v2i13.493